Skip to main content
Medical Reference · Condition Monograph

Multiple System Atrophy

다계통 위축증

A disease in which several nervous systems responsible for autonomic function, movement, and balance degenerate together. Because parkinsonian symptoms overlap with autonomic dysfunction, accurate differential diagnosis and tailored management are important.

History

Multiple system atrophy is a rare neurodegenerative disease that begins in adulthood and progresses gradually. As the name suggests, "multiple neural pathways" are damaged together; typically, motor control (parkinsonism or cerebellar function) and the body's automatic functions (autonomic function) are affected together. In 1960, a form in which "severe orthostatic hypotension (a drop in blood pressure when standing) and parkinsonism appear together" was first described in detail, and for a time afterward it was also called Shy–Drager syndrome. Terms that appeared to belong to the same family, such as olivopontocerebellar atrophy and striatonigral degeneration, were used interchangeably, but as their clinical features overlapped and common pathological findings were confirmed at autopsy, they were consolidated in the 1990s into a single framework called "multiple system atrophy."

Since then, the diagnostic criteria have also changed little by little. Because in many cases autonomic symptoms are not prominent at first, or the disease looks similar to Parkinson's disease, efforts have continued to reduce "the problem of delayed diagnosis." Recent research summarizes that the international diagnostic criteria revised in 2022 can capture the disease better at an early stage (in particular by including supportive imaging findings and the concept of an "early stage (prodromal phase)") and can also help in selecting participants for research and clinical trials.

Historically, the most important point is that the understanding has taken hold that "it cannot be explained by a single symptom." At first, some features such as orthostatic hypotension and parkinsonism were emphasized, but over time, symptoms that disrupt every aspect of daily life, such as urinary disorders, abnormal behavior during sleep, voice changes and swallowing difficulties, and breathing problems, began to be explained as broadly connected. Thanks to this trend, today it is recognized as a disease that is managed over the long term by bringing together neurology, rehabilitation, urology, respiratory and sleep medicine, nutrition, and caregiving.

Causes

A "clear cause" of multiple system atrophy has not yet been identified. However, it is understood as a disease in which a specific protein abnormally clumps and accumulates in the brain, so that nerve cells and the cells that support them (particularly oligodendrocytes) are damaged together. The key protein here is alpha-synuclein (α-synuclein). This protein normally plays an important role in nerve cells, but when for some reason its shape becomes distorted and it clumps together, it can become toxic.

Multiple system atrophy is grouped together with Parkinson's disease in the category of "synucleinopathies," but the location and pattern in which the protein accumulates are different. In Parkinson's disease, Lewy bodies are seen mainly inside nerve cells, whereas in multiple system atrophy, glial cytoplasmic inclusions are characteristically observed inside oligodendrocytes. This difference is thought to influence the clinical features and the rate of progression as well.

It is also important that the cause cannot be neatly explained by a single genetic variant. Most cases occur "sporadically," without a family history. Therefore, it is currently explained that factors such as "genetic predisposition," "environmental factors," "aging," "immune and inflammatory responses," and "the cell's cleanup system (the function that breaks down and processes proteins)" are likely involved in combination. In recent research, the concept of "seeding," in which alpha-synuclein acts like a seed that induces the abnormal aggregation of other proteins, has been drawing attention.

Meanwhile, because there is no "test that can determine the cause," in actual patient care, rather than searching for the cause, the key is "making the diagnosis by combining the pattern of symptoms and test findings, and providing management that reduces dangerous complications (falls, aspiration pneumonia, sudden breathing problems)."

Genetic Epidemiology

Genetic epidemiology is a field that looks at "how much certain genetic factors increase the risk of a disease" at the population level. Because most cases of multiple system atrophy have no family history and it is not a disease in which heredity is clearly confirmed, genetic epidemiology discusses it centered on "genetic variants that may slightly increase risk" or "variants observed more often in certain populations" rather than "causative genes."

Recent research summarizes that variants near the alpha-synuclein gene and variants in genes related to cellular energy metabolism, among others, may be associated with risk in some studies, but results differ by country and ethnicity, and in some cases they are difficult to replicate. For example, there are reports that a certain variant appeared more meaningful in East Asian populations, while the same association was weak or absent in European populations.

An important point in genetic epidemiology is that "association" is not the same as "cause." It is safest to understand that having a certain genetic variant does not mean the disease will definitely develop, but rather that the risk may rise slightly when several conditions coincide. Therefore, from the general reader's point of view, the expectation that "the diagnosis is confirmed if a test finds one or two genes" is far from reality.

Nevertheless, there are two reasons why genetic research is important. First, it can provide clues to understanding the mechanism of the disease. Second, it can help classify patients better in future clinical trials and broaden the possibilities for personalized treatment. Recent research emphasizes the trend of combining large-scale genomic studies with patient registry data from multiple countries.

General Epidemiology

Multiple system atrophy is classified as a very rare disease. A prevalence of a few people per 100,000 population is generally cited, and it actually varies depending on the region and research methods. It most often begins in a person's 50s or 60s, and the male-to-female ratio is reported somewhat differently depending on the study. The disease is described as divided into a form in which parkinsonism is prominent (multiple system atrophy, parkinsonian type, MSA-P) and a form in which cerebellar dysfunction is prominent (multiple system atrophy, cerebellar type, MSA-C), but in actual patients it is also common for the two patterns to appear mixed.

It is also often mentioned that the ratio of MSA-P to MSA-C differs by region. There are reports that MSA-P is relatively more common in Western countries, while MSA-C is more common in East Asia. However, because these differences are also influenced by diagnostic practices, access to medical care, registration systems, and so on, it is difficult to draw firm conclusions.

An important epidemiological point is that "because diagnosis is difficult, it may be counted less often than it actually occurs." In the early stages, it is often approached first as Parkinson's disease, cerebellar ataxia, peripheral autonomic abnormalities, or prostate/bladder problems, so the whole picture of the disease is not seen at once. Autopsy studies have reported that some people who had been diagnosed with Parkinson's disease during life actually had multiple system atrophy, suggesting that cases can be missed with clinical diagnosis alone.

Recent research considers that advances in "patient registries" and "biomarkers" can increase the accuracy of estimates of actual incidence and prevalence. It is also emphasized that, because the disease is rare, multicenter studies in which multiple institutions pool data are especially important.

Pathogenesis

Pathogenesis is the part that explains "why these symptoms arise" in terms of the sites and processes of damage in the brain. In multiple system atrophy, the abnormal accumulation of alpha-synuclein inside oligodendrocytes is known to be the key finding. Oligodendrocytes are cells that produce and maintain the "myelin" that surrounds nerve fibers, helping electrical signals to be transmitted well. When these cells are damaged, nerve signal transmission breaks down, and ultimately multiple circuits are affected at the same time.

The areas of the brain mainly damaged are the basal ganglia, which are related to motor control, the cerebellum, the brainstem (particularly the pons), and the pathways that regulate the autonomic nervous system. That is why parkinsonism (slowness, stiffness, balance problems), cerebellar ataxia (staggering, impaired coordination), and autonomic dysfunction (orthostatic hypotension, urinary and sexual function problems, abnormal sweating) appear together within a single disease.

Recent research has put forward the view that alpha-synuclein can clump into "different shapes (strains)," and that its toxicity or pattern of spread may differ depending on the shape. The "seed-spread" concept, in which abnormal proteins released from nerve cells travel outside the cell to other cells so that pathological changes widen, is also discussed. The inflammatory response is another important pillar. When microglia are activated and inflammatory substances increase in the damaged areas, a vicious cycle can arise in which nerve damage worsens further.

To reduce the pathogenesis to one sentence from the general public's point of view, it is "a disease in which several of the brain's control systems break down at once." That is why treatment, rather than being solved with a single drug, must manage "multiple pillars" such as blood pressure, urination, walking, swallowing, sleep, and breathing at the same time in order to protect quality of life.

Symptoms

Symptoms are the "discomfort that patients feel." The symptoms of multiple system atrophy are easy to understand when grouped into three broad clusters.

The first is parkinsonism, in which movement slows and the body becomes stiff. Walking becomes slow, movements become sluggish, and small movements become difficult. Handwriting may become smaller, and a person may feel unsteady when turning the body or changing direction. Unlike in Parkinson's disease, the response to medication may be weak, or the medication may work a little at first but its effect soon diminishes.

The second is cerebellar symptoms, in which balance and coordination decline. A person walks with a staggering gait, has difficulty keeping their balance, and finds it hard to do fine tasks with the hands. Pronunciation may become slurred or speech may feel broken up.

The third is autonomic symptoms. A person may feel dizzy or have their vision go dark when standing up from sitting, and in severe cases may faint. There may be frequent urination or difficulty holding urine, or conversely, difficulty passing urine with a strong sensation of incomplete emptying. In men, erectile dysfunction sometimes appears as an early symptom. Constipation, abnormal sweating, dry mouth, and difficulty regulating body temperature may also accompany the condition.

In addition, sleep problems are common. Symptoms such as REM sleep behavior disorder (RBD, rapid eye movement sleep behavior disorder), in which a person flails their arms and legs while dreaming, may appear first, and breathing problems such as snoring, sleep apnea, and stridor, a wheezing sound when breathing at night, may also develop. Recent research emphasizes that urinary problems and blood pressure problems can appear relatively early from the beginning of the disease, and that sleep disorders may even precede motor symptoms.

Signs

Signs are "objective findings observed" on examination and testing. The representative signs that raise suspicion of multiple system atrophy are as follows.

First, parkinsonism is clear, but the response to Parkinson's disease medication (levodopa, etc.) is small, or even if there is a response, it is short-lived. Second, autonomic dysfunction is objectively confirmed. A typical example is orthostatic hypotension, in which systolic blood pressure drops by 20 mmHg or more and diastolic blood pressure by 10 mmHg or more when standing up from lying down; a large post-void residual urine on bladder ultrasound, or a neurogenic bladder pattern on urodynamic testing, may also be confirmed.

Third, cerebellar signs or pyramidal signs are present. Coordination of the arms and legs may decline, nystagmus or speech disorders may be seen, or findings such as hyperreflexia may appear together. Fourth, progression is rapid, and postural instability and falls can appear at a relatively early stage.

Fifth, supportive findings may be seen on imaging. On magnetic resonance imaging (MRI), atrophy or signal changes in the striatum (particularly the putamen) may be observed in MSA-P, and pontine and cerebellar atrophy and findings such as the "hot cross bun sign" may be observed in MSA-C. However, in the early stages, imaging may be close to normal or very subtle, so it is difficult to rule out the disease solely because the imaging is "normal." Recent research summarizes that biomarker research is advancing, such as protein deposition on skin biopsy and markers of nerve damage in body fluids.

Screening

"Screening" as understood by the general public is usually closer to "catching early signs that should prompt a person to suspect a problem and go to the hospital." Multiple system atrophy is not a disease screened for through population-based checkups. Instead, the following situations can be considered warning signs that "it may not be typical Parkinson's disease."

① It looks like parkinsonism, but orthostatic dizziness and fainting are present early on, or blood pressure fluctuates severely ② Urinary disorders are prominent from the early stages, with incomplete emptying, urinary urgency, urinary incontinence, and urinary retention worsening rapidly ③ Staggering is prominent, or slurred speech accompanies it at a relatively early stage ④ Dream-enacting behavior during sleep (REM sleep behavior disorder, RBD) or stridor, in which breathing sounds become harsh at night, appears ⑤ Falls increase rapidly, and walking aids become necessary at an early stage

"Simple screening" at medical institutions begins with history-taking and basic measurements. Measuring blood pressure and pulse in the sitting and standing positions to check for orthostatic hypotension, and measuring post-void residual urine with ultrasound, are relatively accessible. In recent research, tests that sensitively detect alpha-synuclein aggregation, blood and cerebrospinal fluid markers reflecting the degree of nerve damage, and image interpretation using artificial intelligence are being studied. At the current stage, "suspecting it early when symptoms are present and connecting the person to specialist care" is the most realistic screening strategy.

Diagnosis

Multiple system atrophy is diagnosed through "the synthesis of multiple pieces of information." A definitive diagnosis is possible only by confirming the characteristic pathological findings at autopsy, but during life, clinical diagnostic criteria are used. The key is to confirm the combination of "autonomic dysfunction + a motor syndrome (parkinsonism or cerebellar syndrome)."

First, taking the medical history is important. The physician specifically checks whether there has been orthostatic dizziness or fainting, when urinary and sexual function problems began and how severe they are, abnormal behavior during sleep, voice changes or swallowing problems, the frequency of falls, and so on. Tests serve to gather "supportive findings." For autonomic testing, measurement of blood pressure changes on standing, the head-up tilt test (HUT), sweat tests, and others may be considered. For urological evaluation, measurement of post-void residual urine, urodynamic testing, and so on are helpful. For imaging, magnetic resonance imaging (MRI) is central, and functional imaging is also consulted as needed.

Recent research emphasizes that the diagnostic criteria revised in 2022 treat certain supportive imaging findings as more important and include a "prodromal (very early stage)" category, aiming to capture, as research participants, patients in whom REM sleep behavior disorder or autonomic dysfunction appears first. In addition, biomarkers such as tests that sensitively detect alpha-synuclein "seeds," skin biopsy–based tests, and markers of nerve damage in blood and cerebrospinal fluid are cited as candidates for increasing diagnostic accuracy.

An indispensable part of diagnosis is differential diagnosis. It must be distinguished from Parkinson's disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), drug-induced parkinsonism, vascular parkinsonism, hereditary cerebellar ataxia, and others. In particular, the combination of "autonomic dysfunction prominent from the early stages," "weak response to levodopa," and "rapid progression" is an important clue.

Treatment

There is currently no established treatment that "stops or reverses" multiple system atrophy. The goals of treatment are to reduce symptoms, prevent complications such as falls, aspiration, and infection, and help maintain daily functioning safely for as long as possible. Therefore, drug therapy, rehabilitation, lifestyle adjustments, and care planning must go together.

For motor symptoms (parkinsonism), levodopa-class drugs can be tried, but the response is often limited. Even when there is a response, it may last only a short time, so the dose is adjusted while balancing it against side effects (worsening of low blood pressure, hallucinations, etc.). Rehabilitation is key for walking and balance. Physical therapy provides gait training and balance training, and when the risk of falls increases, assistive devices such as canes, walkers, and wheelchairs are actively introduced. Occupational therapy helps make daily activities such as eating, dressing, and hygiene safer.

The pillars of autonomic treatment are "blood pressure" and "bladder and urination." For orthostatic hypotension, nonpharmacological measures are the foundation, such as drinking enough water, adjusting salt intake (under medical guidance), compression stockings, sleeping with the head of the bed raised, and avoiding standing up suddenly. As medications, drugs that constrict blood vessels or increase blood volume (e.g., midodrine, etc.) may be used. When supine hypertension is also present, careful adjustment is needed, because treating one side can worsen the other.

Swallowing difficulties and breathing problems directly affect safety and prognosis. Swallowing rehabilitation, adjustment of food texture, and education on preventing aspiration are needed, and as the disease progresses, methods of nutritional support (e.g., feeding tube/gastrostomy) and airway management may be discussed. If there is stridor during sleep, a sleep study and respiratory evaluation are needed, and in some cases airway-related procedures may be required. In recent research, various candidates for "slowing disease progression," such as therapies targeting alpha-synuclein, are being evaluated in clinical trials, but none has yet become established as a standard treatment.

Prognosis

The prognosis varies from person to person, but overall the disease is known to be progressive, with relatively rapid functional decline. Survival after the onset of symptoms is often cited as roughly in the range of 6–12 years, and the median is often described as about 7–10 years. Many patients come to need walking assistance within a few years, and after that they may need to use a wheelchair or require help with all aspects of daily life.

Factors cited as affecting prognosis include the severity of autonomic dysfunction (especially severe orthostatic hypotension), early onset of breathing and swallowing problems, the frequency of falls, and the overall rate of progression. The more severe and earlier the autonomic dysfunction, the more aggressive the overall course may be. Conversely, there are also reports that in forms in which cerebellar symptoms predominate and autonomic problems appear later, the course is relatively more gradual.

Rather than the disease itself "suddenly stopping," the causes of death are often linked to complications. Aspiration pneumonia, recurrent infections (e.g., urinary tract infections), poor nutrition, breathing problems, and, rarely, sudden events during sleep are cited. Therefore, the most realistic way to improve prognosis is "management that reduces complications." In everyday care, it is most important to regularly assess the rate at which symptoms change and the level of function (walking, swallowing, blood pressure stability, etc.).

Prevention

At present, no method is known that reliably "prevents" multiple system atrophy. This is because the cause is not clear and there is insufficient evidence to say that any single lifestyle habit greatly changes the risk. Therefore, it is realistic to think of prevention in two layers.

The first is not "preventing onset" but "preventing progression to severe disease (secondary prevention)." After symptoms begin, reducing complications such as falls, aspiration, infection, and poor nutrition actually has a major impact on quality of life and survival. This includes managing orthostatic hypotension, managing urination, swallowing rehabilitation and dietary adjustment, regular rehabilitation exercise, modifying the home environment (anti-slip measures, installing handrails), and appropriate use of assistive devices.

The second is "early recognition." Because multiple system atrophy can look like other diseases in its early stages, diagnosis is easily delayed. Therefore, when signals such as orthostatic dizziness and fainting, urinary disorders, dream-enacting behavior during sleep, early falls, and voice and swallowing problems are present in addition to symptoms that look like parkinsonism, it is important to seek specialist care quickly. Early diagnosis does not lead directly to a cure, but it allows a management plan that prevents complications and reduces dangerous situations to begin earlier.

Recent research emphasizes the direction of capturing the prodromal phase of the disease to make early intervention possible. In addition, as alpha-synuclein-based biomarkers advance, it is likely that systems for assessing risk "when symptoms are at a very early stage" and connecting people to clinical trials will be further strengthened in the future.

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.